SCHEMBL6992162

SCHEMBL6992162

CCC1Oc2ccc(CNCc3cccs3)cc2NC1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.55
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.45
ALDH1A1 P00352 1/20 0.43
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.43
GFER P55789 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 1/20 0.42
USP2 O75604 1/20 0.42
GAA P10253 1/20 0.42
THRB P10828 1/20 0.41
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6991112 0.92 PARP1 (0.53) PARP1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL6998248 0.87 PARP1 (0.73) PARP1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL7003159 0.85 PARP1 (0.74) PARP1L3MBTL1ALDH1A1MAPK1SMN1; SMN2
SCHEMBL6992164 0.78 HSD17B10 (0.43) PARP1L3MBTL1ALDH1A1MAPK1SMN1; SMN2
SCHEMBL7001004 0.76 PARP1 (0.71) PARP1L3MBTL1ALDH1A1MAPK1SMN1; SMN2
SCHEMBL26311050 0.75 L3MBTL1 (0.53) PARP1MEN1KMT2AL3MBTL1MAPK1
SCHEMBL26310974 0.75 PARP1 (0.53) PARP1MEN1KMT2AL3MBTL1MAPK1
SCHEMBL26310973 0.73 PARP1 (0.49) PARP1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL6992168 0.72 HSD17B10 (0.38) PARP1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL6302991 0.72 PARP1 (0.90) PARP1SMN1; SMN2TP53POLBUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed